Truveris

Digital health company on a mission to align the pharmacy marketplace to drive lower prescription costs and improve human health.

[Truveris @Truveris]

Learn more about how our team of independent experts leverages technology to deliver data-driven, transparent contract offers, helping employers and their broker partners make educated decisions about their pharmacy benefits: https://t.co/uJL4duiE7m

[Truveris @Truveris]

Join Truveris experts on September 27 for a discussion about GLP1s, the Average Manufacturer Price (AMP) Cap in the American Rescue Plan Act, and their impact on pharmacy programs for self-funded plans. #PharmacyBenefits #PharmacyIndustry #GLP1s #AMPCap
https://t.co/Df1UiM2Jp6

[Truveris @Truveris]

This week we discussed how formulary inclusion for biosimilars could impact pharmacy benefits.

As we see PBMs sharing policy decisions, it’s crucial that employers speak with their PBM to see how biosimilars may impact plans.

Watch the full webinar: https://t.co/86bxmsyFUt

[Truveris @Truveris]

This Veterans Day, Truveris honors and celebrates all those who have served and continue to serve with courage and bravery. Thank you for your service 🇺🇸

[Truveris @Truveris]

Truveris is hosting a webinar about how to navigate the wave of biosimilars coming to market on 11/15. Learn how to plan for biosimilars and their industry impact by attending this informative event. Click below to save your spot. #Pharmaceuticals https://t.co/wD8DSRbFjz

[Truveris @Truveris]

Many plan sponsors worry that changing PBMs or pharmacy vendors will cause disruptions. But did you know that your incumbent provider is making changes every year? Learn how to weigh the pros and cons of staying with your PBM. #Pharmaceuticals https://t.co/iQ30NsWqiK

[Truveris @Truveris]

Why is healthcare in the US so expensive - and only continuing to rise in cost? Read this fascinating piece from the Harvard Magazine. #Pharmaceuticals #SpecialtyDrugs #PBM #Truveris https://t.co/qqRKDFxlAE

[Truveris @Truveris]

More and more employers are turning to copay assistance programs like copay accumulators & maximizers to contain pharmacy costs. As these programs become more popular, what should payers know about these cost-saving strategies? https://t.co/XmDrZ2ZE4M

[Truveris @Truveris]

With the biosimilars market on the brink of enormous growth, manufacturers must use these strategies to accelerate time to market without compromising R&D quality or rigor. #Pharmaceuticals #PharmacyBenefits #SpecialtyDrugs #PBM #Truveris https://t.co/i6Kc5zkfg9

[Truveris @Truveris]

Biosimilars are on the rise and payers must start planning for them in their pharmacy benefits. In our upcoming webinar, we'll discuss how to plan for the rise of biosimilars & their effects on specialty costs. Reserve your seat! #Pharmaceuticals https://t.co/uKgk0p32z3

[Truveris @Truveris]

A new study suggests that even though generic drugs offer the US healthcare system over $330 billion in savings a year, patients are still overpaying for generic drugs. Read the study below. #Pharmaceuticals #PharmacyBenefits #SpecialtyDrugs #PBM #Truveris https://t.co/wljZho3njM

[Truveris @Truveris]

Join us for our latest webinar, “The Rise of Biosimilars: How Payers Should Plan for 2023 and Beyond.”

Featuring experts Adrienne Trudell and Joe Thomas, we’ll cover the science and upcoming contractual impacts of biosimilars: https://t.co/MXiN1ekzgH

[Truveris @Truveris]

Since the pandemic began, employee benefits has become more complicated, leaving HR to struggle with a variety of benefits challenges. Read our blog for expert advice on handling the difficulties in managing employee benefits. #Pharmaceuticals https://t.co/WGhZJMh0sl

[Truveris @Truveris]

Did you attend our recent webinar on transparency in the pharmacy ecosystem? Watch the full recording to learn more about transparency for PBMs, PBAs, and other pharmacy vendors. #Pharmaceuticals #PharmacyBenefits #SpecialtyDrugs #PBM #Truveris #Webinar https://t.co/yK4CFz9plU

[Truveris @Truveris]

About 1 in 4 adults say they or their household have not filled a prescription, cut pills in half, or skipped doses in the last year due to the cost. Most of them belong to protected groups. #Pharmaceuticals #SpecialtyDrugs #PBM #Truveris https://t.co/3aJlS6035C

[Truveris @Truveris]

Attention brokers and plan sponsors: Truveris and Mployer Advisor's Pharmacy Benefits 101 webinar is LIVE! Grab your lunch and then click here to join the session: https://t.co/cTZJY9JVo8

[Truveris @Truveris]

More high-cost medications are coming to market, leaving payers to use accumulator & maximizers to limit impact on plans. For life sciences, it’s hard to know which drugs are included in these programs. Are yours? #Pharmaceuticals #SpecialtyDrugs #PBM https://t.co/jM9xwtaTks

[Truveris @Truveris]

Many PBMs and pharmacy vendors are describing themselves as "transparent." What does this really mean? And do "transparent" PBMs take spread? Watch the full recording from our recent webinar on transparency in the pharmacy ecosystem. #Pharmaceuticals https://t.co/1k5flUtojJ

[Truveris @Truveris]

According to the American Hospital Association, the median launch price of a brand name drug in 2008 was $2,115 annually. In 2021, that number grew to over $180,000 annually. #Pharmaceuticals #PharmacyBenefits #SpecialtyDrugs #PBM #Truveris https://t.co/r2WXWNuooe

[Truveris @Truveris]

Our team just keeps growing! ��� Please help us offer a very warm welcome to two new Truverians: Erika and Anthony! We are thrilled to have this dynamic duo onboard. 🎉

Visit https://t.co/yZgP2xqpkn to see our open roles.

[Truveris @Truveris]

Need to pick up a few CEU credits? Join Truveris and Mployer Advisor for our "Pharmacy Benefits 101" webinar on October 19th. We'll dig into the prescription drug landscape, PBM contracting strategies, and ways to control costs. Save your seat here: https://t.co/rfb80wGX2X